Join the Lymphoma group to help and get support from people like you.
Lymphoma News (Page 2)
Related terms: Cancer, Lymphoma
Many With Relapsed/Refractory Lymphoma in Pregnancy Delay Treatment
TUESDAY, June 6, 2023 – Most women with relapsed/refractory lymphoma during pregnancy defer therapy and there are few obstetric or neonatal complications, according to a study published online June...
What to Do When Tough-to-Treat Lymphoma Strikes During Pregnancy
FRIDAY, June 2, 2023 – Not a lot is known about how physicians should handle cases in which a pregnant woman is diagnosed with relapsed/refractory lymphoma. A new study may provide some perspective....
Epkinly Granted Accelerated FDA Approval for Lymphoma
MONDAY, May 22, 2023 – The U.S. Food and Drug Administration has granted accelerated approval to Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL),...
Small Increase in Lymphoma Risk Seen With Crohn Disease, Ulcerative Colitis
WEDNESDAY, May 10, 2023 – Crohn disease (CD) and ulcerative colitis (UC) are associated with a slightly increased risk for lymphoma, according to a study published online April 13 in Clinical...
Calquence Tablet Formulation Approved in the US Across Current indications
New formulation can be co-administered with gastric acid-reducing agents Tablet offers equivalent efficacy, safety and consistent dosing compared to current capsule 5 August 2022 – AstraZeneca’s n...
FDA Medwatch Alert: Drug Safety Communication: Copiktra (duvelisib) - FDA Warns about Possible Increased Risk of Death and Serious Side Effects
ISSUE: The FDA is warning that results from a clinical trial show a possible increased risk of death with Copiktra (duvelisib) compared to another medicine to treat a chronic blood cancer called...
FDA Medwatch Alert: FDA Approval of Lymphoma Medicine Ukoniq (umbralisib) is Withdrawn Due to Safety Concerns
June 1, 2022 – Due to safety concerns, the U.S. Food and Drug Administration (FDA) has withdrawn its approval for the cancer medicine Ukoniq (umbralisib). Ukoniq was approved to treat two specific...
Yescarta Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
SANTA MONICA, Calif.--(BUSINESS WIRE)--Apr. 1, 2022-- Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved Yescarta® (axicabtagene ...
U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta Showing Prophylactic Steroid Use Improves Management of Cytokine Release Syndrome
SANTA MONICA, Calif.--(BUSINESS WIRE)--Jan. 31, 2022-- Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved an update to the prescribing...
U.S. FDA Grants Brukinsa (zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE) September 15, 2021 – BeiGene Co.,Ltd (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative...
FDA Approves Ukoniq (umbralisib) for Marginal Zone Lymphoma and Follicular Lymphoma
NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) – TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the U.S. Food and Drug Administration (FDA) has approved Ukoniq (umbralisib), for the treatment of...
Pfizer’s Xalkori (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults
NEW YORK--(BUSINESS WIRE) January 14, 2021 – Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for...
FDA Approves Brukinsa (zanubrutinib) for the Treatment of Mantle Cell Lymphoma
CAMBRIDGE, Mass. and BEIJING, China, Nov. 14, 2019 (GLOBE NEWSWIRE) – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
FDA Grants Genentech’s Polivy (polatuzumab vedotin-piiq) Accelerated Approval for Adults With Previously Treated Aggressive Lymphoma
South San Francisco, CA – June 10, 2019 – Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Polivy...
FDA Approves Revlimid (lenalidomide) In Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma
SUMMIT, N.J.--(BUSINESS WIRE) May 28, 2019 – Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) approved Revlimid (lenalidomide) in combination with a...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Non-Hodgkin's Lymphoma, Blood Disorders